Jasper Therapeutics (JSPR) AI Stock Analysis

• Market Cap: $75.71M
• Dividend Yield: N/A
• Average Volume (3M): 160.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.44
• Revenue Growth: N/A
• EPS Growth: 21.40%
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -1.41
• Shares Outstanding: 15,022,122
• 10 Day Avg. Volume: 156,059
• 30 Day Avg. Volume: 160,168
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $57.63
• Price Target Upside: 1083.37% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

• Rating: 35 Underperform
• Price Target: ―

Jasper Therapeutics faces significant financial challenges with a lack of revenue and ongoing losses, leading to a low financial performance score. The technical analysis indicates bearish momentum, and the negative valuation metrics highlight the stock's unattractiveness. Without earnings call data or notable corporate events, the overall outlook remains concerning.

Positive Factors

Clinical Trial Progress

Jasper Therapeutics announced significant progress across its briquilimab programs, showing continued advancement in their clinical trials.

Efficacy and Safety

Previous data demonstrated continued tolerability and a favorable safety profile for briquilimab, supporting further clinical study plans.

Market Opportunities

BEACON now includes omalizumab-naive patients, which could grow the addressable population for JSPR.

Negative Factors

Financial Needs

With a cash balance of just over $70 million at the end of 2024, Jasper will clearly need to raise additional capital or secure a partnership to advance briquilimab development.

Jasper Therapeutics Business Overview & Revenue Model

Company Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

How the Company Makes Money

Jasper Therapeutics makes money primarily through the development and commercialization of its proprietary therapies. Revenue streams include potential licensing agreements, partnerships with pharmaceutical companies, and the eventual sales of approved products. The company may also receive funding through research grants and collaboration agreements which support the advancement of its clinical trials. Strategic partnerships with other biotech and pharmaceutical companies contribute significantly to its revenue by providing both financial support and collaborative opportunities to expand its research and development capabilities.

Jasper Therapeutics Financial Statement Overview

Summary

Jasper Therapeutics' financial position is precarious, characterized by a lack of revenue, substantial operating losses, and reliance on external financing. While the balance sheet appears stable for now, continuous cash burn and no revenue generation may challenge future viability. The company must achieve revenue generation to improve financial health and sustainability.

Income Statement

Jasper Therapeutics has consistently reported zero revenue, indicating a lack of commercialized products or services. The company has significant and increasing EBIT and net losses, reflecting high operational costs without offsetting income. This performance suggests severe profitability challenges and raises concerns about long-term sustainability.

Balance Sheet

The company maintains a relatively healthy equity position, with stockholders' equity exceeding total liabilities, resulting in a low debt-to-equity ratio. However, the absence of revenue and ongoing losses are depleting equity, posing risks to future financial stability.

Cash Flow

Jasper Therapeutics reports negative operating and free cash flows, reflecting cash burn without revenue generation. Financing activities, primarily through equity financing, have been necessary to support operations. The lack of cash flow from operations presents a significant risk to liquidity and solvency.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-1.11M	-1.31M	-566.00K	-21.00K
	EBIT
-76.24M	-68.86M	-51.20M	-36.83M	-20.68M
	EBITDA
-76.24M	-64.98M	-38.21M	-31.17M	-31.95M
	Net Income Common Stockholders
0.00	-64.47M	-24.17M	-23.98M	-31.67M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
71.64M	86.89M	38.25M	84.70M	19.84M
	Total Assets
79.90M	94.89M	48.36M	93.65M	23.36M
	Total Debt
1.81M	2.79M	3.65M	2.88M	1.62M
	Net Debt
-69.82M	-84.10M	-34.60M	-81.82M	-18.21M
	Total Liabilities
18.23M	16.45M	12.37M	24.14M	58.49M
	Stockholders Equity
61.67M	78.44M	35.99M	69.52M	-35.13M
Cash Flow		Free Cash Flow
-63.15M	-52.33M	-46.43M	-36.11M	-18.27M
	Operating Cash Flow
-62.60M	-52.07M	-45.86M	-33.68M	-18.27M
	Investing Cash Flow
-532.00K	-267.00K	-576.00K	-2.43M	198.34K
	Financing Cash Flow
47.88M	100.97M	55.00K	100.97M	11.29M

Jasper Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.87
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JSPR, the sentiment is Negative. The current price of 4.87 is below the 20-day moving average (MA) of 4.91, above the 50-day MA of 4.67, and below the 200-day MA of 13.33, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 51.57 is Neutral, neither overbought nor oversold. The STOCH value of 62.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JSPR.

Jasper Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.14B	3.03	-43.89%	2.83%	16.75%	-0.06%
CBUS	42 Neutral	$95.25M	―	-157.73%	―	104.78%	40.41%
IFRX	40 Underperform	$122.18M	―	-62.38%	―	178.84%	-40.60%
CABA	39 Underperform	$90.32M	―	-73.85%	―	―	-40.59%
VTGN	39 Underperform	$70.13M	―	-46.28%	―	-33.00%	54.91%
JSPR	35 Underperform	$75.71M	―	-101.34%	―	―	21.40%
RENB		$57.38M	―	-67.13%	―	―	―

Jasper Therapeutics Corporate Events

Jasper Therapeutics Signs New Sales Agreement with Jefferies

On March 19, 2025, Jasper Therapeutics entered into a Sales Agreement with Jefferies LLC to potentially sell up to $100 million in common stock, providing flexibility in capital raising. The company also terminated its previous sales agreement with Cantor Fitzgerald & Co. on March 14, 2025, without incurring material penalties, having not sold any shares under that agreement.